Xue Jun Gao

Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial

Guizhen Wu, Jin Zhang, W. Lei, 2022, Signal Transduction and Targeted Therapy.

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial

Guizhen Wu, Jin Zhang, W. Lei, 2022, Nature Communications.